ES2229820T3 - Terapia de combinacion ribavirina-interferon alfa para erradicar el hcv-rna detectable en pacientes con infeccion por hepatitis c cronica. - Google Patents

Terapia de combinacion ribavirina-interferon alfa para erradicar el hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.

Info

Publication number
ES2229820T3
ES2229820T3 ES99970662T ES99970662T ES2229820T3 ES 2229820 T3 ES2229820 T3 ES 2229820T3 ES 99970662 T ES99970662 T ES 99970662T ES 99970662 T ES99970662 T ES 99970662T ES 2229820 T3 ES2229820 T3 ES 2229820T3
Authority
ES
Spain
Prior art keywords
compound
formula
baselineskip
represented
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99970662T
Other languages
English (en)
Spanish (es)
Inventor
Ashit K. Ganguly
Jinping Mccormick
Raymond G. Lovey
Frank Bennett
Anil K. Saksena
Viyyoor M. Girijavallabhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/348,534 external-priority patent/US6277830B1/en
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2229820T3 publication Critical patent/ES2229820T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
ES99970662T 1998-10-16 1999-10-14 Terapia de combinacion ribavirina-interferon alfa para erradicar el hcv-rna detectable en pacientes con infeccion por hepatitis c cronica. Expired - Lifetime ES2229820T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US174059 1988-03-28
US17405998A 1998-10-16 1998-10-16
US348534 1999-07-07
US09/348,534 US6277830B1 (en) 1998-10-16 1999-07-07 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon

Publications (1)

Publication Number Publication Date
ES2229820T3 true ES2229820T3 (es) 2005-04-16

Family

ID=26869824

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99970662T Expired - Lifetime ES2229820T3 (es) 1998-10-16 1999-10-14 Terapia de combinacion ribavirina-interferon alfa para erradicar el hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.

Country Status (20)

Country Link
EP (1) EP1121369B1 (https=)
JP (1) JP2002527522A (https=)
CN (1) CN1330658A (https=)
AT (1) ATE284408T1 (https=)
AU (1) AU762395B2 (https=)
BR (1) BR9915546A (https=)
CA (1) CA2346447C (https=)
CZ (1) CZ20011130A3 (https=)
DE (1) DE69922529T2 (https=)
ES (1) ES2229820T3 (https=)
HU (1) HUP0200447A2 (https=)
ID (1) ID29187A (https=)
IL (1) IL142423A0 (https=)
NO (1) NO20011789L (https=)
NZ (1) NZ510811A (https=)
PL (1) PL347268A1 (https=)
RU (1) RU2001113268A (https=)
SK (1) SK4742001A3 (https=)
TR (1) TR200101085T2 (https=)
WO (1) WO2000023454A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924270B2 (en) 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
WO2004084796A2 (en) * 2003-03-28 2004-10-07 Pharmasset Ltd. Compounds for the treatment of flaviviridae infections
JP2007501806A (ja) * 2003-08-13 2007-02-01 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー ウィルス感染を治療する方法
WO2005049065A2 (en) * 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
JP2008540425A (ja) 2005-05-02 2008-11-20 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝可能部分を含む複素環式抗ウイルス性化合物およびその使用
WO2009028575A1 (ja) 2007-08-27 2009-03-05 National University Corporation Nagoya University 血液凝固第vii因子プロモーターの活性化剤及びその利用
WO2009028573A1 (ja) 2007-08-27 2009-03-05 National University Corporation Nagoya University 血液凝固障害におけるリバビリンの利用
WO2011151667A1 (en) 2010-06-02 2011-12-08 Adbula Kurkayev Antiviral compositions
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CA3033867A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
CN107513055B (zh) * 2017-08-11 2018-06-22 广东昊邦医药健康有限责任公司 一种利巴韦林衍生化合物及其药物组合物
CN117355311A (zh) 2022-05-05 2024-01-05 阿卜杜拉·库尔卡耶夫 用于恢复生物体生理过程和细胞的药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1482736A (en) * 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
US4544741A (en) * 1982-03-29 1985-10-01 Robins Roland K Azole dinucleotide compounds and methods for their production
US4925930A (en) * 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
WO1998021223A1 (en) * 1996-11-12 1998-05-22 Medivir Ab Nucleosides

Also Published As

Publication number Publication date
TR200101085T2 (tr) 2001-08-21
CA2346447A1 (en) 2000-04-27
SK4742001A3 (en) 2001-11-06
AU762395B2 (en) 2003-06-26
CZ20011130A3 (cs) 2001-08-15
CN1330658A (zh) 2002-01-09
WO2000023454A1 (en) 2000-04-27
NO20011789D0 (no) 2001-04-09
ATE284408T1 (de) 2004-12-15
CA2346447C (en) 2006-01-31
DE69922529T2 (de) 2005-12-15
IL142423A0 (en) 2002-03-10
BR9915546A (pt) 2001-08-14
DE69922529D1 (de) 2005-01-13
HUP0200447A2 (en) 2002-06-29
ID29187A (id) 2001-08-09
EP1121369B1 (en) 2004-12-08
AU1197500A (en) 2000-05-08
JP2002527522A (ja) 2002-08-27
PL347268A1 (en) 2002-03-25
NZ510811A (en) 2003-06-30
EP1121369A1 (en) 2001-08-08
RU2001113268A (ru) 2003-09-27
NO20011789L (no) 2001-06-11

Similar Documents

Publication Publication Date Title
ES2229820T3 (es) Terapia de combinacion ribavirina-interferon alfa para erradicar el hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.
US6924270B2 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6403564B1 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6277830B1 (en) 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US7608599B2 (en) Antiviral phosphoramidates
AU2003288064B2 (en) Antiviral nucleoside derivatives
ES2278009T3 (es) Derivados de nucleosidos como inhibidores de la arn polimerasa virica dependiente de arn.
US6673775B2 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
JP2006507235A (ja) フラビウイルス科ウイルス感染治療のためのビシクロ［４．２．１］ノナン系を有する化合物
HUP0300027A2 (en) Nucleoside analogs with carboxamidine modified monocyclic base and process for their use
CA2384326A1 (en) Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
ZA200503936B (en) Antiviral nucleoside derivatives